Mortality and complications after prostate biopsy in the Prostate, Lung, Colorectal and Ovarian Cancer Screening (PLCO) trial

BJU International

Volumn 113, Issue 2, 2014, Pages 254-259

  Pinsky, Paul F ^a   Parnes, Howard L ^a   Andriole, Gerald ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

complications; mortality; prostate biopsy; prostate specific antigen; PSA

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER MORTALITY; CANCER SCREENING; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FOLLOW UP; HUMAN; HUMAN TISSUE; IATROGENIC DISEASE; INFECTIOUS COMPLICATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORBIDITY; MULTICENTER STUDY; OVARY CANCER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

COMPLICATIONS; MORTALITY; PROSTATE BIOPSY; PROSTATE-SPECIFIC ANTIGEN; PSA;

AGED; BIOPSY; EARLY DETECTION OF CANCER; HUMANS; HYPERTROPHY; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROSTATITIS; QUESTIONNAIRES; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84892534272     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12368     Document Type: Article

References (12)

1. Loeb S, Carter HB, Berndt S, Ricker W, Schaeffer E,. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186: 1830-1834
2. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183: 936-969
3. Pinkhasov GI, Lin Y, Palmerola R, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits-experience from 1000 consecutive cases. Br J Urol Int 2012; 110: 369-374
4. Rosario DJ, Lane JA, Metcalfe C, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation with ProtecT study. Br J Med 2012; 344: d7894
5. Loeb S, van den Heuvel S, Zhi X, et al. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol 2012; 61: 1110-1114
6. Gallina A, Suardi N, Montorsi F, et al. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. Int J Cancer 2008; 123: 647-652
7. Boniol M, Boyle P, Autier P, Ruffion A, Perrin P,. Critical role of prostate biopsy mortality in the number of year of life gained and lost within a prostate cancer screening program. Br J Urol Int 2012; 110: 1648-1653
8. Andriole GA, Crawford ED, Grubb R, et al. Mortality Results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319
9. Andriole GL, Crawford ED, Grubb R, et al. Screening for Prostate Cancer, 13-year update of the results of the prostate component of the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. J Natl Cancer Inst 2012; 104: 1-8
10. Prorok P, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21: 273S-309S
11. Carlsson SV, Holmberg E, Moss SM, et al. No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. Br J Urol Int 2010; 107: 1912-1917
12. Pinsky PF, Miller A, Kramer BS, et al. Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Am J Epidemiol 2007; 165: 874-881